CRC for Mental Health

Australian Science Shines for Pfizer

The CRC for Mental Health was highlighted in the Australian Trade Commission’s case study, ‘Australian Science Shines for Pfizer’. The article features Dr. Daniel Grant (Head of External R&D Innovation Pfizer Australia), as he speaks about Pfizer’s involvement in Australian science, saying “Australia has some of the world’s best academics in areas such as oncology, immunology and neurology.”  Twitter_logo_blue_16 He believes that “creating and maintaining an operating environment that recognises innovation and in turn can attract the growing investment attached to the discovery and development of, in particular, biologics or large molecules, has “the potential to return significant benefits to the Australian economy.” Twitter_logo_blue_16

Pfizer is an important industry participant of the CRC for Mental Health. Dr. Grant describes the work of the CRC as “very exciting” and reaffirms Pfizer’s interest in looking “to grow our interaction with the collaborating partners and in doing so progress the important work of discovering early biomarkers that have the potential to advance the development of new therapies for the treatment of neurodegenerative disease, psychoses, and mood disorders.” He emphasizes that Pfizer has been an “active participant in many of the Australian government’s programs that are designed to support collaborations between companies and academic research groups, such as the Australian Research Council Linkage grants and CRC program,” highlighting the importance of collaborative research in Australia.

Read the full article

Investment_CaseStudy_Pfizer_thumbnail

 

Comments are closed.